LG and ENERGY STAR Power Up Earth Day Savings With Exclusive Retailer Offers Nationwide
ENGLEWOOD CLIFFS, N.J., April 22, 2025 /3BL/ - ENERGY STAR® Partner of the Year LG Electronics USA is encouraging consumers to make their energy choices count this Earth Day and beyond. Through May 14, smart choices come with big savings thanks to LG's nationwide in-store and online ENERGY STAR promotions.
By investing in LG's high-efficiency appliances, shoppers make energy choices that deliver savings for years to come. In celebration of Earth Day 2025, LG and retailers across the country are making it easy to make practical and energy-smart upgrades.
Through LG.com and participating national and regional retailers, LG's ENERGY STAR 'Appliance Bundle Savings' program offers tiered rebates designed to reward families creating more efficient homes:
This Earth Day, shoppers have more choices than ever. In 2025, LG is the brand with the most ENERGY STAR certified cooking products (ranges, ovens and cooktops), residential clothes dryers, clothes washers, laundry centers, and refrigerator-freezers. What's more, LG is second to none in the number of ENERGY STAR certified OLED TVs on the market.
Another Earth Day promotion features LG's heat pump dryer (model DLHC5502). Designated ENERGY STAR Most Efficient 2025, it uses 65 percent less energy per load than conventional dryers for energy savings that are good for your energy bill. Through April 23, LG.com shoppers can purchase it with an eligible washer for $400 off, plus up to an extra $100 off with trade-in.
Smart energy choices lower your energy bills and improve the health and comfort of your home. According to the U.S. Environmental Protection Agency, there are the top three ways you can save with energy choices:
To explore LG's Earth Day offers and ENERGY STAR certified appliances-, visit www.lg.com/us/promotions.
# # #
About LG Electronics USALG Electronics USA Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics Inc., a smart life solutions company with annual global revenues of more than $60 billion. In the United States, LG sells a wide range of innovative home appliances, home entertainment products, commercial displays, air conditioning systems and vehicle components. LG is an 11-time ENERGY STAR® Partner of the Year. www.LG.com.
Media Contacts:
John I. Taylor [email protected] +1 201 816 2166
Marianne Ortiz [email protected] +1 484 557 8873
Visit 3BL Media to see more multimedia and stories from LG Electronics USA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hypebeast
4 hours ago
- Hypebeast
ASICS GT-2160 'Black/Morpho' Delivers Bold Contrast and Retro Appeal
Name:ASICS GT-2160 'Black/Morpho'Colorway:'Black/Morpho'SKU:1203A275-003MSRP:$130 USDRelease Date:Available NowWhere to Buy:ASICS TheASICSGT-2160receives a vibrant and intriguing addition with its new 'Black/Morpho' colorway. This iteration continues to pay homage to the technical design language of the GT-2000 series from the early 2010s, while its colorway draws inspiration from the striking black morpho tetra fish. The silhouette combines a stealthy black mesh upper with vivid green and blue overlays, creating a bold visual contrast that highlights the shoe's intricate details. Metallic silver elements are strategically incorporated into the design, further elevating the visual appeal, all sitting atop an off-white sole unit that completes the dynamic look. Emblematic features from the GT-2000 are also carried over, including a segmented midsole structure and visible GEL® technology inserts. This combination not only creates an industrial aesthetic but also provides advanced cushioning properties, enhancing comfort.
Yahoo
4 hours ago
- Yahoo
KiWear Unveils Smart Ring Input Solution for AI Glasses in Collaboration with Qualcomm at AWE USA 2025
Collaboration addresses interactive solutions for smart glasses as global smart glasses shipments surge 210%i year-over-year LONG BEACH, Calif., June 10, 2025--(BUSINESS WIRE)--KiWear, Inc. today announced a reference design for a smart ring input solution for use with smart glasses and AI glasses during Qualcomm Technologies, Inc.'s opening keynote presentation at AWE USA 2025. The collaboration aims to help OEMs develop interactive solutions for AI smart glass partners. Industry analysts expect 60% year-over-year growth in 2025 and a sustained CAGR of over 60% through 2029. "Qualcomm Technologies is fueling the AI glasses industry with our Snapdragon® XR Platforms. KiWear's smart ring, featuring algorithms co-developed with Qualcomm Technologies, makes an ideal input device for smart glasses and AI glasses," said Ziad Asghar, SVP & GM of XR at Qualcomm Technologies, Inc. "This new reference design represents a step forward in helping OEMs to deliver solutions that enable intuitive and discreet gesture based interaction for the growing category of AI smart glasses. "We are thrilled to build next generation input solutions for both AI and XR together with industry leaders such as Qualcomm," said Chris Shi, Founder and CEO of KiWear, Inc. Leading HCI Innovation KiWear, recognized as a leader in HCI innovations, has developed cutting-edge smart ring technology that enables seamless hand-centric interactions with smart glasses and AI glasses. The company's solutions address fundamental input challenges that have limited widespread smart glasses adoption. Founded in April 2025, KiWear is a Delaware-based company delivering comprehensive HCI solutions for multi-DoF controllers, smart rings, and wearables. The company brings together prominent computer vision scientists, AI/XR integration experts, and hardware/software innovators, with expertise spanning conceptualization to mass production. KiWear has forged collaborations and delivers exclusive solutions to six of the global top 10 consumer electronics leaders. With R&D hubs in Shanghai and Beijing beyond its U.S. headquarters, the company partners with premier technology conglomerates to enable natural HCI solutions for next-generation XR and AI products. Live Demonstrations Conference attendees can experience KiWear's smart ring and watch technologies at the Qualcomm Technologies' booth (Booth 209) during AWE USA, showcasing seamless integration with smart glasses platforms. Snapdragon is a trademark or registered trademark of Qualcomm Incorporated. Snapdragon branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. __________________________ i Source: View source version on Contacts Media Contact:Sally GaoKiWear +86-13918187350
